Table 1.
Baseline characteristics of included trials.
| Study | Country | Study Design | Study Group | No of Patient’s |
Age, Years | Sex, Male, n, % | NOS Score |
|---|---|---|---|---|---|---|---|
| Acet et al., 2015 [18] | Turkey | Retrospective study | Normal flow | 88 | 60.2 ± 14.3 | 72 (81.8%) |
9 |
| No-flow | 236 | 62.1 ± 13.9 | 165 (69.9%) |
||||
| Adam et al., 2018 [19] | Pakistan | Prospective cohort study | MACE-positive | 102 | 54.49 ± 11.41 | 68 (66.7%) |
8 |
| MACE-negative | 195 | 55.82 ± 10.50 | 120 (61.5%) | ||||
| Cao et al., 2023 [20] | China | Retrospective study | AMI | 284 | 61.27 ± 12.01 | 237 (83.45%) | 9 |
| No-AMI | 91 | 59.10 ± 11.96 | 51 (56.04%) | ||||
| Celık et al., 2016 [21] | Turkey | Retrospective study | Normal flow | 198 | 62 ± 11 | 144 (72.7%) | 8 |
| No-flow | 382 | 58 ± 12 | 307 (80.4%) | ||||
| Chen et al., 2023 [22] | China | Single-center, observational, retro- spective study | AMI With Death | 94 | 76.61 ± 11.98 | 53 (56.38%) | 8 |
| AMI Without Death | 94 | 76.88 ± 9.04 | 48 (51.06%) | ||||
| Dziedzic et al., 2023 [23] | Poland | Retrospective study | AMI | 103 | 73.1 ± 9.9 | NS | 8 |
| No-AMI | 135 | 71.1 ± 8.3 | NS | ||||
| Guclu et al., 2020 [24] | Turkey | Prospective cohort study | AMI With Death | 22 | 68.09 + 18.7 | 10 (45.5%) |
9 |
| AMI Without Death | 148 | 61.5 + 10.6 | 120 (81.1%) |
||||
| Harun et al., 2016 [25] | Indonesia | Retrospective study | AMI | 223 | NS | 151 (67.71%) | 7 |
| No-AMI | 198 | NS | 84 (42.42%) | ||||
| Karadeniz et al., 2023 [26] | Turkey | Retrospective, cross-sectional study | MACE-positive | 195 | 65.3 ± 10.8 | 123 (63.1%) | 8 |
| MACE-negative | 908 | 76.6 ± 11.3 | 636 (70.0%) | ||||
| Kurtul et al., 2014 [27] | Turkey | Retrospective, cross-sectional study | Normal flow | 403 | 58 ± 12 | 311 (77.2%) | 8 |
| No-flow | 117 | 68 ± 13 | 74 (63.2%) |
||||
| Li et al., 2020 [28] | China | Retrospective study | MACE-positive | 81 | NS | NS | 7 |
| MACE-negative | 421 | NS | NS | ||||
| Li et al., 2022 [29] | China | Single-center prospective observational study | MACE-positive | 107 | NS | 78 (72.9%) |
8 |
| MACE-negative | 1594 | NS | 1227 (77.0%) | ||||
| Pashapour et al., 2019 [30] | Iran | Retrospective, cross-sectional study | MACE-positive | 47 | 63.13 ± 13.14 | 38 (80.9%) |
8 |
| MACE-negative | 270 | 59.54 ± 11.70 | 225 (83.3%) | ||||
| Senoz et al., 2021 [31] | Turkey | Retrospective study | Normal flow | 204 | 57.29 ± 13.14 | 152 (74.5%) |
9 |
| No-flow | 43 | 61.74 ± 12.47 | 27 (62.8%) |
||||
| Sheng et al., 2021 [32] | China | Prospective cohort study | STEMI | 24 | 71.1 ± 9.8 | 12 (50.0%) |
8 |
| NSTEMI | 25 | 66.5 ± 10.8 | 18 (72.0%) |
||||
| UA | 156 | 63.6 ± 10.6 | 108 (69.5%) |
||||
| Shumilah et al., 2021 [33] | Yemen | Case–control study | AMI | 100 | 55.5 ± 15 | 60 (60.0%) |
7 |
| No-AMI | 100 | 54.1 ± 15 | 60 (60.0%) |
||||
| Wang et al., 2018 [34] | China | Retrospective study | Normal flow | 515 | 62 ± 13 | 368 (71.5%) | 8 |
| No-flow | 97 | 63 ± 16 | 29 (69.1%) |
||||
| Wang et al., 2021 [35] | China | Prospective observational study | MACE-positive | 96 | 71 (63~78) | NS | 7 |
| MACE-negative | 291 | 67 (59~75) | NS | ||||
| Zhou et al., 2016 [36] | China | Retrospective study | MACE-positive | 572 | 62.93 ± 11.18 | 361 (63.11%) | 8 |
| MACE-negative | 1658 | 58.12 ± 11.31 | 934 (56.33%) |
Legend: AMI: acute myocardial infarction; DM: diabetes mellitus; MACE: major advance cardiac event; NOS: Newcastle Ottawa Scale; NS: not specified; and UA: unstable angina.